NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.
William J Gradishar, Meena S Moran, Jame Abraham...
https://pubmed.ncbi.nlm.nih.gov/41213254/Actively Recruiting
Led by SWOG Cancer Research Network · Updated on 2025-11-05
2400
Participants Needed
963
Research Sites
N/A
Total Duration
Researchers are evaluating a phase III trial comparing shorter chemotherapy-immunotherapy without anthracycline drugs to the usual chemo-immunotherapy for treating early-stage triple negative breast cancer TNBC. This study aims to see if the shorter treatment works as well as the usual anthracycline-containing treatment. The trial also assesses patient-reported outcomes like fatigue and physical function, as well as safety and survival measures. It involves participants with specific stages of TNBC and includes detailed evaluations of tumor response and immune markers. Participants are randomly assigned to one of two treatment groups. One group receives paclitaxel, carboplatin, and pembrolizumab followed by doxorubicin, cyclophosphamide, and pembrolizumab, then surgery, with possible pembrolizumab after surgery. The other group receives docetaxel, carboplatin, and pembrolizumab prior to surgery, with possible pembrolizumab after surgery. Blood samples may be collected throughout the trial for research purposes. During the study, participants undergo surgery after chemotherapy-immunotherapy. They are followed every six months for two years, then annually up to five years. Assessments include breast cancer event-free survival, pathological response, distant relapse-free survival, overall survival, adverse events, and patient-reported fatigue and physical function. Quality of life and other patient-reported symptoms are also evaluated. Specimens are banked for future research. The total participation may last up to five years from registration.
CONDITIONS
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
A
Alicia Aranda
D
Dana Sparks
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
SWOG Cancer Research Network
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Shorter chemo-immunotherapy (no anthracycline) | Usual chemo-immunotherapy (includes anthracycline) | Guideline chemo-immunotherapy (with anthracycline) |
|---|---|---|---|
| What is this approach? | Experimental multi-agent chemo-immunotherapy with pembrolizumab, carboplatin, paclitaxel, docetaxel, and cyclophosphamide, omitting anthracycline (doxorubicin), given for a shorter duration before surgery. | Multi-agent chemo-immunotherapy combining pembrolizumab with standard-dose doxorubicin (an anthracycline), cyclophosphamide, paclitaxel, and other agents given before surgery. | Current guideline-recommended neoadjuvant therapy for stage II/III triple-negative breast cancer includes pembrolizumab with multi-agent chemotherapy (anthracycline plus taxane-based regimen) before surgery. |
| Role in this trial | Evaluated as a shorter, anthracycline-free potential alternative to usual chemo-immunotherapy. | Represents the current standard-of-care regimen randomized as the active comparator for investigational comparison. | Serves as the guideline standard used outside the trial for most eligible patients. |
| Primary use | Investigate whether a shorter, anthracycline-free neoadjuvant regimen is as effective in reducing recurrence risk as the current standard. | Reduce the risk of recurrence or progression in early-stage TNBC when given prior to surgery as neoadjuvant therapy. | Improve event-free and overall survival in patients with early-stage, high-risk triple-negative breast cancer before surgery. |
| How is it given? | Cycles of intravenous chemotherapy (carboplatin, cyclophosphamide, paclitaxel, docetaxel) and pembrolizumab, omitting doxorubicin, delivered over a reduced time period before surgery. | Given as cycles of intravenous chemotherapy (doxorubicin, cyclophosphamide, paclitaxel) plus pembrolizumab prior to surgery. | Multidrug chemotherapy protocol with pembrolizumab, using anthracycline and taxane agents, given intravenously in cycles prior to surgery. |
| Evidence status | Effectiveness and safety are under investigation; results pending from this current randomized trial. | Efficacy and safety are well supported by prospective randomized studies and reflected in national guidelines. | Efficacy and safety profiles are well established by multiple large clinical trials and are summarized in current guidelines. |
| Important limitations | Benefits and risks remain unproven for this shorter, anthracycline-free regimen. Long-term recurrence and survival data are not yet available. | Anthracycline-containing regimens have established benefits but carry risks of heart damage and other significant toxicities, particularly with cumulative doses. | Anthracycline-based standard regimens have long-term toxicity concerns and are not suitable for patients with significant cardiac risk or anthracycline contraindications. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to several months until surgery and possible additional pembrolizumab after surgery
Participants receive neoadjuvant chemotherapy and immunotherapy. Those in Arm I receive paclitaxel, carboplatin, and pembrolizumab followed by doxorubicin, cyclophosphamide, and pembrolizumab. Those in Arm II receive docetaxel, carboplatin, and pembrolizumab. Treatment is followed by surgery. Participants may also receive pembrolizumab after surgery. Blood samples may be collected throughout the trial.
Multiple treatment visits with intravenous infusions and surgery visit
Duration - Up to 5 years
Participants are followed up for safety, disease status, and patient-reported outcomes every 6 months for the first 2 years and then annually until 5 years from registration.
Visits every 6 months for 2 years, then annual visits up to 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
William J Gradishar, Meena S Moran, Jame Abraham...
https://pubmed.ncbi.nlm.nih.gov/41213254/SWOG Cancer Research Network
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor